Hikma asks FDA to bless its bovine-sourced heparin; Pfizer gets restraining order against Nigerian police; and much more

> As traditional heparin makers stumble on contaminated supplies of raw material obtained from pigs, Jordanian generics firm Hikma is asking for FDA approval to sell the blood thinner in the U.S.--and its products are made from Argentine cows. Report

> The Lagos High Court in Nigeria granted Pfizer's request for a restraining order to stop state police from harrassing the drugmaker's current and former employees, and awarded the company about $4,200 in damages. Report

> Aventis Pharma launched a pre-filled, disposable insulin pen, soloSTAR, in India. Report

> Chemicals maker BASF is expanding its capability to make amines used in pharmaceuticals manufacturing. Release

> Dynavax is dropping its mid-stage ragweed allergy drug Tolamba as it failed to meet its primary efficacy endpoint. Report

> In an interview with the Financial Times, outgoing GSK CEO Jean-Pierre Garnier shares his thought on the new, tougher FDA approval environment. Report

> Pharmacopeia's shares were up today on trial results for PS433540, a hypertension drug. Report

Emerging Drug Developer: Auspex Pharmaceuticals. Report

And Finally... Prescription meds are supplanting illegal substances as drugs of choice. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.